anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Session 1- Review of initial sleep diary, formulation of impression of type/subtype of insomnia, determine modifiable factors, address immediate concerns about participation, discuss motivation \& compliance. Session 2- Review of sleep diary, present 4-P model of insomnia, prescribe Sleep Restriction \& Stimulus Control Therapy. Session 3- Review of sleep diary, continue with stimulus control \& sleep restriction procedures, review of sleep hygiene. Session 4- Review of sleep diary, continue with stimulus control \& sleep restriction procedures, introduce \& practice relaxation strategies. Session 5- Review of sleep diary, continue with stimulus control \& sleep restriction procedures, conduct cognitive therapy to address dysfunctional thoughts underlying insomnia. Session 6- Review of sleep diary, continue with stimulus control \& sleep restriction procedures Session 7- Review of sleep diary \& overall progress, discuss relapse prevention, further sleep restriction guidelines \& prophylaxis.
BACKGROUND: Diet is among the most influential lifestyle factors impacting chronic disease risk. Nutrimetabolomics, the application of metabolomics to nutrition research, allows for the detection of food-specific compounds (FSCs) that can be used to connect dietary patterns, such as a Mediterranean-style (MED) diet, to health. This validation study is based upon analyses from a controlled feeding MED intervention, where our team identified FSCs from eight foods that can be detected in biospecimens after consumption and may therefore serve as food intake biomarkers.
METHODS: Individuals with overweight/obesity who do not habitually consume a MED dietary pattern will complete a 16-week randomized, multi-intervention, semi-controlled feeding study of isocaloric dietary interventions: (1) MED-amplified dietary pattern, containing 500 kcal/day from eight MED target foods: avocado, basil, cherry, chickpea, oat, red bell pepper, walnut, and a protein source (alternating between salmon or unprocessed, lean beef), and (2) habitual/Western dietary pattern, containing 500 kcal/day from six non-MED target foods: cheesecake, chocolate frozen yogurt, refined grain bread, sour cream, white potato, and unprocessed, lean beef. After a 2-week washout, participants complete four, 4-week intervention periods, with biospecimen sampling and outcome assessments at baseline and at intervention weeks 4, 8, 12, and 16. The primary outcome is change in the relative abundance of FSCs from the eight MED target foods in participant biospecimens from baseline to the end of each intervention period. Secondary outcomes include mean change in cardiometabolic health indicators, inflammatory markers, and adipokines. Exploratory outcomes include change in diversity and community composition of the gut microbiota.
DISCUSSION: Our stepwise strategy, beginning with identification of FSCs in whole diets and biospecimens, followed by relating these to health indicators will lead to improved methodology for assessment of dietary patterns and a better understanding of the relationship between food and health. This study will serve as a first step toward validating candidate food intake biomarkers and allow for assessment of relationships with cardiometabolic health. The identification of food intake biomarkers is critical to future research and has implications spanning health promotion and disease prevention for many chronic conditions.
TRIAL REGISTRATION: Registered at ClinicalTrials.gov: NCT05500976 ; Date of registration: August 15, 2022.
The PROAIR RESPICLICK inhaler has a dose counter attached to the actuator. When the patient receives the inhaler, the number 200 will be displayed. The dose counter will count down each time the inhaler is actuated. When the dose counter reaches 20, the color of the numbers will change to red to remind the patient to contact their pharmacist for a refill of medication or consult their physician for a prescription refill. When the dose counter reaches 0, the background will change to solid red. Discard PROAIR RESPICLICK 13 months after opening the foil pouch, when the dose counter displays 0 or after the expiration date on the product, whichever comes first [see Patient Counseling Information (17)].
Investigators will prospectively enroll 200 adult participants referred to the Johns Hopkins Hospital for catheter ablation of atrial fibrillation (AF). Investigators will first enroll participants with paroxysmal AF (n=100) to complete sensitivity analysis of inflammatory fat and potential target identification before enrolling participants with persistent AF (n=100). All participants (n=200) will undergo pre-procedural CT using the ultra-high resolution CT scanner 3-4 days prior the ablation procedure to allow a sufficient amount of time for image processing. In all participants (n=200), blood specimens will be collected immediately prior to the ablation procedure. The participants with paroxysmal AF (n=100) will receive the standard of care, which is PVI, and the clinical outcome will be followed up to 12 months post-procedure. In this group, investigators will conduct a sensitivity analysis to define the range of peri-left atrial (LA) fat tissue (in HU) that is associated with AF recurrence. Investigators will also conduct computation of source-sink mismatch arising from wall thinning due to fat infiltration into the myocardium that favors functional block and local reentry. For participants with persistent AF (n=100), investigators will conduct an exploratory clinical trial where the participants will be randomly assigned to 1) PVI group (n=50), or 2) PVI + inflammatory fat-targeted ablation group (n=50). In the latter group, additional focal ablation will be performed beyond PVI to target the inflammatory fat tissue based on the result of the sensitivity analysis. Randomization will be performed with the use of an automated computer-generated randomization algorithm. The participants will be unaware of the group assignment, but the operators will not be blinded (single-blinded design). In all patients, no ablation strategies beyond PVI except cavotricuspid isthmus (CTI) ablation for typical atrial flutter (AFL) will be allowed, such as linear lesions (e.g. roof lines, mitral isthmus lines), and focal ablation to eliminate complex fractionated atrial electrograms (CFAE) and rotating drivers.
The present invention discloses an anti-CD20 chimeric antibody which comprises a human IgG1, K constant region and a variable mouse source region. The amino acid sequence of a light chain is shown in a sequence table SEQ ID No. 1, and the amino acid sequence of a heavy chain is shown in a sequence table SEQ ID No. 2. The chimeric antibody is used for preparing medicines for treating B lymphocyte cancer. The preservation number of a CHO cell strain for expressing the anti-CD20 chimeric antibody is CGMCC1400. The present invention provides a new anti-CD20 chimeric antibody which has preferable antigen binding capacity and high killing effect after being purified. Compared with a mouse antibody, the chimeric antibody not only reserves the high compatibility of the variable mouse source region but also has the panimmunity killing function of a human Fc fragment. Thereby, the reactive incidence rate of a human anti-mouse antibody is reduced greatly, and the clinic therapeutic effect is improved. Compared with other genetic engineering antibodies with small molecules, the chimeric antibody as a complete antibody molecule has a long half-life period in vivo, and has the panimmunity killing function of the human Fc fragment.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to (S)-α-phenyl-2-pyridine ethaneamine of the formula (I) and its salts with inorganic acids showing anticonvulsant activity (value α = 3.7 mg/kg). Invention relates to also a drug showing anticonvulsant effect and containing a substance of the formula (I) taken at effective amount and pharmaceutically acceptable additions. Invention relates to also a method of treatment of patients with convulsions by administration of therapeutically effective dose of compound (I). Invention relates to also a method of synthesis of compound (I) that involves treatment of racemic ED 50 -phenyl-2-pyridine ethaneamine with chiral acid followed by selective precipitation of diastereomeric salt. EFFECT: improved method of synthesis, enhanced effectiveness of compound. 8 cl, 1 dwg, 2 ex
Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance \[CrCl\].
Rationale: Nab-paclitaxel (Abx) is widely employed in malignant tumor therapy. In tumor cells and pro-tumoral M2-type macrophages, the IL4 receptor (IL4R) is upregulated. This study aimed to elucidate the selective delivery of Abx to M2-type macrophages by targeting IL4R and reprogramming them into an anti-tumoral M1-type. Methods: Abx was conjugated with the IL4R-binding IL4RPep-1 peptide using click chemistry (IL4R-Abx). Cellular internalization, macrophage reprogramming and signal pathways, and tumor growth and metastasis by IL4R-Abx were examined. Results: IL4R-Abx was internalized into M2 macrophages more efficiently compared to the unmodified Abx and control peptide-conjugated Abx (Ctrl-Abx), which was primarily inhibited using an anti-IL4R antibody and a receptor-mediated endocytosis inhibitor compared with a macropinocytosis inhibitor. IL4R-Abx reprogrammed the M2-type macrophages into M1-like phenotype and increased reactive oxygen species (ROS) levels and extracellular release of high mobility group box 1 (HMGB1) in M2 macrophages at higher levels than Abx and Ctrl-Abx. The conditioned medium of IL4R-Abx-treated M2 macrophages skewed M2 macrophages into the M1-like phenotype, in which an anti-HMGB1 antibody and a toll-like receptor 4 (TLR4) inhibitor induced a blockade. IL4R-Abx accumulated at tumors, heightened immune-stimulatory cells while reducing immune-suppressing cells, and hampered tumor growth and metastasis in mice more efficiently than Abx and Ctrl-Abx. Conclusions: These results indicate that IL4R-targeting allows enhancement of M2-macrophage shaping into M1-like phenotype by Abx through the ROS-HMGB1-TLR4 axis, improvement of antitumor immunity, and thereby inhibition of tumor growth and metastasis, presenting a new approach to cancer immunotherapy.
PURPOSE: A pharmaceutical composition containing a free MHC-I formation inhibitor is provided to reduce free MHC-I amount and to prevent and treat dementia. CONSTITUTION: A pharmaceutical composition for preventing and treating dementia contains a free MHC(major histocompatibility complex)-I formation inhibitor as an active ingredient. The free MHC-I forming inhibitor is beta 2-microglobulin. The dementia is Alzheimer's disease. The pharmaceutical composition additionally contains a carrier, excpient, disintegrant, sweetener, expander, lubricant, flavoring agent, antioxidant, buffer solution, diluents, binder, or dispersing agent. The pharmaceutical composition is manufacturing the form of granule, powder, coating tablet, tablet, pills, capsule, suppository, juice, suspension, emulsion, or liquid.
Physical exercise program. The experimental programme is an add-on to usual care and consists of an aerobe graded exercise program performed twice a week for 12 weeks. Usual care includes all public treatments that each patient is assigned to at entry to REPCon. The provision of officially available treatments follow the Danish Health Care Act.
ONM-501 will be administered as intratumoral injections once per week for three weeks followed by three weeks without ONM-501 administration. Each dosing cycle will be 21 days. The combination agent will be administered according to standard protocol, once every three weeks.
This disclosure relates to methods for measuring one or more physiological signals while the user is engaged in a predetermined activity. Exemplary predetermined activities can include activities such as walking, climbing stairs, biking, and the like. The physiological measurements can include, but are not limited to, heart rate signals. The physiological measurements may be affected by the predetermined activity, so the system may be configured to employ one or more criteria prior to measuring physiological information to minimize the effects. The one or more criteria can include, but are not limited to, an inter-sampling waiting time, continuous motion criteria, predetermined activity criteria, a post-physiological measurement amount of time, and a confidence value. The continuous motion criteria can be based on the type of predetermined activity. For example, walking may have walking state criteria and a step count criteria.
The invention provides a Chinese medicinal composition buckwheat toxin-expelling pill, and the composition contains buckwheat, radix astragali, gentrin knotweed, wild chrysanthemum flower and honey. The invention also relates to applications of the Chinese medicinal compound buckwheat toxin-expelling pill, in reinforcing the healthy qi and eliminating the pathogenic factors, clearing heat and expelling toxin, dispersing swelling and relieving pain, and applications in preparing medicines for curing skin anabrosis and muscle ulcer. It is indicated by experiment results that the Chinese medicinal compound in a different proportion can be used to cure skin anabrosis, muscle carbuncle and the like caused by healthy qi deficiency with excess of the pathogenic factors and exuberant inferior heat. The Chinese medicinal compound buckwheat toxin-expelling pill of the invention can be used to cure gastrodynia, indigestion, anabrosis, innominate inflammatory, traumatic injury, rheumatic arthritis and the like. Additionally, the Chinese medicinal compound of the invention is extensive in drug source and low in cost, and a preparation method is simple and easy to operate. The formula has characteristics of being reasonable in drug compatibility, definite in curative effect, without toxic side effect, controllable in quality standard and easy to absorb.
Compositions for inhibiting beta secretase activity are disclosed. Compositions that enhance bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin, a-turmerone, ar- turmerone, or, sesamolin are disclosed. Some compositions include a curcuminoid mixture and essential oil of turmeric having a-turmerone. Some compositions include a curcuminoid mixture and a combination, wherein the combination includes essential oil of turmeric having a-turmerone, and, an extract of sesame oil having sesamolin. Some compositions are a combination of essential oil of turmeric having a-turmerone, and, an extract of sesame oil having sesamolin. Methods of preparing the compositions are disclosed. Methods of treatment of central nervous system or neurological disorders are provided.
BACKGROUND: The use of mesh is the standard for the prevention of incisional hernia (IH). However, the effect of surgical site occurrence (SSO) has never been compared. The aim of this meta-analysis was to evaluate the prevalence of SSO and measure its negative effect through the calculation of the number needed to treat for net effect (NNT net).
METHODS: A meta-analysis was performed according to the PRISMA guidelines. The primary objective was to determine the prevalence of SSO and IH, and the secondary objective was to determine the NNT net as a metric to measure the combined benefits and harms. Only published clinical trials were included. The risk of bias was analyzed, and the random effects model was used to determine statistical significance.
RESULTS: A total of 15 studies comparing 2344 patients were included. The incidence of IH was significantly lower in the mesh group than in the control group, with an OR of 0.29 (95% CI 0.16-0.49, p = 0.0001). The incidence of SSO was higher in the mesh group than in the control group, with an OR of 1.21 (95% CI 0.85-1.72, p = 0.0001) but without statistical significance. Therefore, the way to compare the benefits and risks of each of the studies was done with the calculation of the NNT net, which is the average number of patients who need to be treated to see the benefit exceeding the harm by one event, and the result was 5, which is the average number of patients who need to be treated to see the benefit exceeding the harm by one event.
CONCLUSION: The use of mesh reduces the prevalence of IH and it does not increases the prevalence of SSO, the NNT net determined that the use of mesh continues to be beneficial for the patient.
Stillbirth is a fundamental component of childhood mortality, but its causes are still insufficiently understood. This study aims to explore stillbirth risk factors by using a multidisciplinary approach to stimulate public policies and protocols to prevent stillbirth, improve maternal care and support bereaved families. METHODS AND ANALYSIS: In this case-control study with stillbirths and live births in 14 public hospitals in São Paulo, mothers are interviewed at hospitals after delivery, and hospital records and prenatal care registries are reviewed. Maternal and umbilical cord blood samples and placentas are collected to analyse angiogenesis and infection biomarkers, and the placenta's anatomopathological exam. Air pollutant exposure is estimated through the participant's residence and work addresses. Traditional and non-invasive autopsies by image-guided histopathology are conducted in a subset of stillbirths. Subsample mothers of cases are interviewed at home 2 months after delivery on how they were dealing with grief. Information contained in the official prenatal care registries of cases and controls is being compiled. Hospital managers are interviewed about the care offered to stillbirth mothers. Data analysis will identify the main risk factors for stillbirth, investigate their interrelations, and evaluate health services care and support for bereaved families. We hope this project will contribute to the understanding of stillbirth's risk factors and related health services in Brazil, providing new knowledge about this central public health problem, contributing to the improvement of public policies and prenatal and puerperal care, helping to prevent stillbirths and improve the healthcare and support for bereaved families. ETHICS AND DISSEMINATION: This study protocol was approved by the Ethics Committee of the Municipal Health Secretary (process no 16509319.0.3012.5551) and of the Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (process no 16509319.0.0000.0068). Results will be communicated to the study participants, policy-makers and the scientific community.
CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.
Intervention I: Over a period of two months, healthcare professionals will ask standardized questions about exposure to violence using a questionnaire that measures exposure to physical, psychological, and sexual violence over the past 12 months. These questions will be verbally asked to all patients visiting the care units, regardless of the reason for their visit.
Patients in the intervention group will recieve a \~1000mg capsule containing \~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant.
A decision system includes a dynamic biomedical graph configured to provide multiple functions. Through dynamic variation of the biomedical graph structure a more optimal segregation of a diverse set of inputs can be identified. A decision process by which a conclusion is reached can be viewed as a path through the biomedical graph. In contrast with a typical “black box” neural network, this approach clarifies how and why a particular conclusion was reached. Such clarification can lead to identification of new and/or unexpected relationships between input data and resulting conclusions, and also provide confidence that the conclusion was based on a sensible decision process. The decision system is applied, as an example, to medical decisions made in In Vitro Fertilization (IVF).
MAXALT is a medication used for the treatment of migraine attacks in adults. MAXALT is a member of a class of drugs called selective 5-HT1B/1D receptor agonists.

It is available as a traditional tablet (MAXALT) and as an orally disintegrating tablet (MAXALT-MLT1). Unless otherwise stated, the information contained in this leaflet applies both to MAXALT Tablets and to MAXALT-MLT Orally Disintegrating Tablets.

Tell your doctor about your symptoms. Your doctor will decide if you have migraine. Use MAXALT only for a migraine attack. MAXALT should not be used to treat headaches that might be caused by other, more serious conditions.

You will find more information about migraine at the end of this leaflet.
Grass mix sublingual allergy immunotherapy drops One single-dose container (0.5 ml) once daily. 50 SRU/day for five consecutive days followed by 150 SRU/day for five additional consecutive days. Maintenance: 300 SRU/day from day 11.
The HOME intervention is the delivery of an in-home, family inclusive, rehabilitation intervention in eight sessions. Six of the sessions will occur in the home, and two will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
Patients will receive at least one injection of Intramuscular (IM) olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
The invention relates to a vascular embolic agent, which is composed of liquid metal and/or liquid metal alloy. The liquid metal and liquid metal alloy have the melting points below 60 DEG C and density larger than that of blood, are non-toxic. The vascular embolic agent can be mixed with nano particles or radioactive elements or chemotherapeutics. The invention also provides an injection device of the vascular embolic agent, which has heating and temperature measuring functions. The vascular embolic agent can be used as an imaging equipment contrast agent or a tumor thermotherapy sensitizer, and can be used for preparing tumor radiotherapy and chemotherapeutics drugs. The vascular embolic agent can be extracted from the blood vessel after treatment.
The invention relates a method for improving bioavailability of resveratrol. The method is simple and convenient and can be operated easily. The method overcomes the defects of the prior art and adopts a modern pellet-forming technology. Through deep analysis of physical and chemical properties of resveratrol, based on a dissolution rate as an index, an excipient and a binder as medicinal auxiliary materials are determined by scientific tests. The method utilizes a small amount of the auxiliary materials, has stable quality, good effect reproducibility, and a low adverse reaction occurrence rate. Pellets obtained by the method can be distributed on a large area of the surface of an absorption organ so that human relative bioavailability F is improved to 85.42% from 76.75% and local stimulation is reduced and more choices are provided for consumers.